Sanket Koul

Govt to intensify surveillance, audits against unauthorised GLP-1 sales

Online pharmacies, drug wholesalers under scanner; non-compliance may lead penalties, license cancellations

Blackstone-backed ASK Property Fund exits Mahagun's project for ₹650 cr

ASK Property Fund has exited Mahagun's Noida project with Rs 650 crore, earning a 21 per cent IRR, as the stalled development sees revival following NCLT relief

Domestic medtech lobby seeks govt support as key input costs rise 50%

Domestic medical device makers seek government support as input costs surge up to 50 per cent amid West Asia disruptions, flagging supply chain stress and rising logistics costs

Somerset Indus closes $288 mn fund, eyes larger healthcare investments

Somerset Indus has closed its third fund at $288 million, exceeding its target, and plans larger investments across healthcare, medtech, and insurance-linked sectors

CDSCO flags 4 spurious drugs, 194 fail quality tests in February 2026

CDSCO flagged four drugs as spurious and 194 as not of standard quality in February 2026, including widely used medicines, as part of routine surveillance

Semaglutide prices crash up to 90% as 15+ generics launch in two days

Off-patent GLP-1 therapy drives 70-90% price drop with generics flooding in

NCLT allows withdrawal of insolvency process against ATS Knightsbridge

ATS eyes delivery of project in 18 to 24 months, reset in core NCR luxury market

Dr Reddy's enters semaglutide market, launches diabetes generic drug

Drugmaker expects to receive regulatory approval for weightloss sema generic in a few months

Semaglutide generics may fuel rush for cosmetic weight loss, warn doctors

As semaglutide goes off patent, doctors warn of misuse by non-obese individuals amid rising demand driven by social media and lower-cost generics

Hormuz blockade may lead to increase in ultra-luxury house prices by 5%

Forced reroutes from Hormuz for ships carrying construction material may raise input costs, delay timelines and push up ultra-luxury housing prices in key cities

Homeland Group, VRC acquire Mohali land parcels for over ₹1,000 crore

Homeland Group and VRC acquire two prime land parcels in Mohali via GMADA auction, planning large mixed-use projects with premium residential and commercial spaces

Companies eye alternatives after CDSCO bans weight-loss drug ads

Firms may shift to doctor outreach, CME programmes and patient support initiatives as CDSCO bars advertising of GLP-1 drugs ahead of semaglutide patent expiry

Health Ministry asks institutes to avoid informal foreign engagements

Union Health Ministry directs research bodies to refrain from informal data sharing and collaborations with foreign agencies without prior approval from competent authorities

Gulshan group ties up with IHCL for Taj-branded residences in Noida

Realty company to invest ₹1,000 crore in project featuring 57 floors; construction to be completed by 2031

Morning-after pills: DTAB pushes for boxed warnings, stricter norms

CDSCO's DTAB panel proposes boxed warnings on emergency contraceptive pills and inclusion under Schedule K to ensure safer usage while retaining over-the-counter availability

Delhi HC seeks response from Centre, CDSCO over misuse of diabetes drugs

The matter has been posted for hearing on May 21

West Asia crisis: Reality check gets India on investors' realty list

UAE citizens, NRIs, family offices, regional investment groups evaluating India to broaden their allocation strategies

India's challenge to evergreening: 2026 may test drug patent regime

Experts say 2026 could be a crucial year for drug patents, with the likely emergence of fresh disputes over follow-on patents

CDSCO mandates online applications for manufacture, sale of r-DNA drugs

CDSCO has mandated online submission of applications for licences to manufacture and sell r-DNA-origin drugs through the ONDLS portal to streamline regulatory processes

India's REIT market grows 6-fold since FY20 on listings, price gains: CBRE

India's REIT market has grown more than six-fold since FY20 to Rs 1,726 billion in the first nine months of FY26, supported by new listings and steady unit price appreciation, CBRE said